A randomized, controlled phase 2 trial of uproleselan, an e-selectin inhibitor, vs placebo to reduce GI toxicity in patients with multiple myeloma undergoing autologous hematopoietic cell transplant-MedSci.cn

A randomized, controlled phase 2 trial of uproleselan, an e-selectin inhibitor, vs placebo to reduce GI toxicity in patients with multiple myeloma undergoing autologous hematopoietic cell transplant

Crees, Z; Stockerl-Goldstein, K; Ryan, M; Gao, F; Christen, B; Mayeski, C; Slade, M; Schroeder, M; Vij, R; DiPersio, J; Uy, G

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023; 23 (): S292

科室
- - 订阅+
  - 更多科室
工具
服务